dihomo γ linolenic acid

Ethyl dihomo-γ-linolenic acid ethyl ester (ethyl DGLA), an ω-6 fatty acid intermediate ester form, elevates prostaglandin E1(PGE1) and PGE2 secretion in rabbit renal papilla when administered dietarily at a dosage of 1 g/kg per day for 25 days. Additionally, this dosage of ethyl DGLA increases triglyceride levels and enhances the proportion of 20:3ω6 and 20:4ω6 phospholipids in the renal medulla of rabbits. Ethyl DGLA formulations have been employed in managing eczema and inflammatory disorders.

Dihomo-γ-linolenic acid (DGLA; all-cis-8,11,14-Eicosatrienoic acid) sodium, a 20-carbon ω-6 fatty acid, exhibits anti-inflammatory and anti-proliferative properties. It has been shown to mitigate atherosclerosis in the apolipoprotein E deficient mouse model system [1] [2] [3].

Dihomo-γ-Linolenic acid methyl ester is the methyl ester form of Dihomo-γ-Linolenic acid which has anti-inflammatory and anti-proliferative effects.

12(S)-HETrE is an endogenous metabolite produced by oxidation of ω-6 PUFA dihomo-γ-linolenic acid (DGLA) by 12-lipoxygenase (12-LOX) in platelets, which acts on Gαs-coupled G-protein-coupled receptors, has antithrombotic properties, and has potential therapeutic use in cardiovascular disease. 12(S)-HETrE is reported to inhibit agonist-mediated platelet activation (IC50 = 40 μM), α granule secretion, integrin αIIbβ3 activation, Rap1 activation, and thrombin-induced clot retraction in vitro.

8(S)-HETrE is a monohydroxy polyunsaturated fatty acid produced by rabbit neutrophil lipoxygenase when dihomo-γ-linolenic acid is used as a substrate. Although the biological activities of 8(S)-HETrE have not been well characterized, it is expected to behave similarly to 8(S)-HETE .

8,11,14-Eicosatrienoic acid, also known as dihomo-γ-linolenic acid , is a polyunsaturated fatty acid (PUFA) produced from γ-linolenic acid by the action of fatty acid elongases. It can be metabolized by the cyclooxygenase pathway to produce 1-series prostaglandins (PGs) (e.g., PGE1). (±)14(15)-EpEDE is an EpEDE acid formed from 8,11,14-eicosatrienoic acid. This monoepoxide can be generated from the PUFA, in vitro, by the action of a strong oxidizing agent. Alternatively, this compound may be produced, in vivo, by epoxidation of the PUFA by cytochrome P450 epoxygenases. The biological properties of this compound are poorly understood.

Prostaglandin D1 (PGD1) is the theoretical D-series metabolite of dihomo-γ-linolenic acid (DGLA), but to date it has not been isolated as a natural product. It is an inhibitor of ADP-induced platelet aggregation in humans with an IC50 value of 320 ng/ml, about 1/10 as potent as PGD2. 13,14-dihydro-15-keto Prostaglandin D1 (13,14-dihydro-15-keto PGD1) is the theoretical metabolite of PGD1 via the 15-hydroxy PG dehydrogenase metabolic pathway. No biological studies for this compound have been reported.

15(S)-HETrE is the hydroxy-trienoic acid resulting from 15-lipoxygenation of dihomo-γ-linolenic acid. It inhibits 5-LO in human PMNL with an IC50 value of 4.6 μM. In RBL cells, 15(S)-HETrE also inhibits 5-LO, but is approximately 1/20 as potent as 15(S)-HpETE.

Prostaglandin F1α (PGF1α) is a lipid mediator and an endogenous metabolite of prostacyclin, primarily metabolised from DGLA via the COX pathway, and can dose-dependently regulate smooth muscle contraction.

Prostaglandin E1 (PGE1), synthesized through cyclooxygenase-mediated metabolism of dihomo-γ-linolenic acid (DGLA), functions by inhibiting platelet aggregation (IC50= 40 nM) and enhancing vasodilation. Its analog, 13,14-dihydro-16,16-difluoro PGE1, and the metabolite, 13,14-dihydro PGE1, both retain similar anti-aggregatory properties to the original compound. The inclusion of two electron-withdrawing fluorine atoms in 13,14-dihydro-16,16-difluoro PGE1 is believed to increase molecular stability and potentially extend bioavailability by resisting hydrolytic degradation.

Dihomo-γ-linolenic acid (Standard) is a reference standard for Dihomo-γ-linolenic acid, suitable for quantitative analysis, quality control, and biochemical experiments. Dihomo-γ-linolenic acid (DGLA) is a fatty acid widely present in plants, exhibiting antitumor and antiproliferative effects.

Dihomo-γ-Linolenic acid methyl ester (Standard) is the standard substance of Dihomo-γ-Linolenic acid methyl ester, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Dihomo-γ-Linolenic acid methyl ester is the methyl ester form of Dihomo-γ-Linolenic acid which has anti-inflammatory and anti-proliferative effects.

Dihomo-γ-linolenic acid (DGLA) is a fatty acid widely found in plants with antitumor and antiproliferative effects, inhibits the growth of xenograft tumor cells, and can be used in the study of inflammation-related diseases such as rheumatoid arthritis, atherosclerosis, and atopic dermatitis.